Physician profile
Michael V Karing
NPI 1356346746
$11,409.86
in general payments reported to CMS, 2019-2025
55 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,368 · 2020: $594 · 2021: $1,767 · 2022: $1,916 · 2023: $2,012 · 2024: $1,999 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,745 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,745.02 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,206.03 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,097.60 | 2020-2025 | |
| Novo Nordisk INC | $991.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $963.89 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $907.37 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $652.82 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $450.79 | 2021-2025 | |
| Astellas Pharma US INC | $447.79 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $443.22 | 2019-2025 | |
| Abbott Laboratories | $389.62 | 2019-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $383.77 | 2019-2022 | |
| Amgen INC. | $382.21 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Janssen Pharmaceuticals, INC | $328.68 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $228.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $217.09 | 2019-2024 | Belsomra, Steglatro, Dificid |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Karing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.